Randomized Trial of Bifidobacterium adolescentis iVS-1 Probiotic to Improve Biological Aging and Metabolic Health in Adults Aged 40 to 75

What this Trial Is About

Researchers are evaluating the effects of Bifidobacterium adolescentis iVS-1 supplementation on biological aging markers, metabolic health, and functional health outcomes in adults aged 40 to 75 years. The study explores how changes in the gut microbiome may influence aging-related biological pathways and overall health. Aging involves changes such as inflammation, cellular aging, mitochondrial function, and gut microbiome alterations, which this trial aims to address through probiotic intervention. Participants will be randomly assigned to receive either a probiotic capsule containing at least 8 billion CFU of Bifidobacterium adolescentis iVS-1 or a placebo capsule once daily for 150 days. This double-blind, placebo-controlled trial includes two groups one taking the probiotic and one taking placebo. The study will collect blood and stool samples and use questionnaires to assess cognition, sleep quality, and quality of life at the start, mid-intervention, and at the end of the 150-day treatment period. During the study, participants will undergo various assessments including biological aging biomarkers, metabolic health measures, lipid profiles, and functional health outcomes. Researchers will monitor changes in cognitive function, sleep quality, and overall quality of life. The primary outcome is the change in biological aging biomarkers from baseline to day 150. This study allows for thorough monitoring of health changes over the treatment period to better understand the probiotics impact on aging processes.

iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults